홈 › 간암 (간세포암종) › 워싱턴
워싱턴의 간암 (간세포암종) 임상 시험
간암 (간세포암종) 관련 연구 15개가 워싱턴 내 여러 지역에서 참여자를 모집하고 있습니다.
워싱턴의 도시
공식 연구 텍스트(영어)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
피험자 모집 중건강한 지원자 환영
45세 ~ 75세 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Seattle
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07227012A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0083, Seattle
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07291076GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Fred Hutchinson Cancer Center, University of Washington, Seattle
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Seattle
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06921785A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
피험자 모집 중2상
8세 이상 · 모든 성별 · 2026. 7. 27. 업데이트됨 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
피험자 모집 중
18세 ~ 75세 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT05486572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 22. 업데이트됨 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Virginia Mason Medical Center, Seattle
- Summit Cancer Centers - North Spokane, Spokane
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 27. 업데이트됨 · NCT05440708Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia
- Northwest Medical Specialties PLLC (NWMS), Tacoma
피험자 모집 중1상
18세 ~ 65세 · 모든 성별 · 2026. 3. 16. 업데이트됨 · NCT07176650Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Seattle Children's Hospital, Seattle
피험자 모집 중1상
1세 ~ 26세 · 모든 성별 · 2026. 2. 17. 업데이트됨 · NCT07148050A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 11. 21. 업데이트됨 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.